Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as oral tablets for oral use. It is used for the prevention of malaria and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in adults and children. GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial agent used to prevent and treat malaria infections. - Prevention of malaria: provides chemoprophylaxis for travelers and residents in endemic regions. - Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: achieves rapid parasite clearance. - Chemoprophylaxis for malaria in high‑risk populations: offers protection when exposure risk is high.

Malarone may cause a range of adverse reactions. Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: occasional cramping or discomfort. - Diarrhea: loose stools that may be watery. Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or hepatitis. - Hematologic disorders: neutropenia or anemia. - Allergic reactions: including anaphylaxis or severe rash.

Before using Malarone, consider the following safety measures. - Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown safety; assess potential infant exposure. - Renal impairment: dose adjustment may be required in severe dysfunction. - Concomitant hepatic enzyme modulators: monitor for altered drug levels. - Hypersensitivity: avoid in patients with known allergy to atovaquone or proguanil. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Malarone can interact with several medicines; review the following categories. Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone and proguanil plasma concentrations. - Protease inhibitor antiretrovirals: may increase proguanil levels, risking toxicity. - CYP2C8 inhibitors (e.g., gemfibrozil): raise atovaquone exposure. - Antacids containing aluminum or magnesium: decrease atovaquone absorption. Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Sulfonamides: potential additive effect on folate pathways, monitor for hematologic changes.